Please assess the completion status of the following clinical trial:

Trial Title: CBT as an Adjunct to SRIs in the Treatment of BDD

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 16-65~* A diagnosis of DSM-IV BDD or its delusional variant (delusional disorder, somatic type)~* Ability to communicate meaningfully with the investigators~* Competent to provide written consent, if over 18 years old, or competent to provide written assent, if 16-17 years, 11 months~* Parental consent, if under 18 years old~* For phase two: must be on a stable therapeutic dose of one of the following SRI medications for at least 8 weeks: fluoxetine, fluvoxamine, venlafaxine, clomipramine, paroxetine, citalopram, or sertraline.~Exclusion Criteria:~* current or lifetime diagnosis of any DSM_IV psychotic disorder not attributable to delusional BDD, current or lifetime diagnosis of DSM-IV bipolar disorder,~* current or recent (within 2 months of study entry) DSM-IV alcohol or substance dependence or abuse,~* recent suicide attempt, or suicidal ideation that warrants consideration of hospitalization,~* need for inpatient or partial hospital treatment,~* use of any medication prescribed for the treatment of BDD other than SRIs, including tricyclic antidepressants, buspirone, or neuroleptics,~* presence of any significant and/or unstable medical condition,~* females who are pregnant or breast-feeding, or who are sexually active and not using adequate contraception.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Body dysmorphic disorder (Type: EXPERIMENTAL): Participants with body dysmorphic disorder

Based on this trial design, predict the completion outcome and termination type (if applicable).